Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...

When a renowned Israeli TV journalist lost his ability to speak clearly because of ALS, he thought his career might be over.

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Google’s ( GOOGL) anti-aging company Calico released disappointing trial results of its first ever drug.

In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

A study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, ...

Denali Therapeutics shares reversed higher on Tuesday after the drugmaker's ALS treatment failed in a six-month study.

Neurosense entered a binding term sheet with a global pharmaceutical company to advance development and commercialization of ...

(NASDAQ:ARGX – Free Report) had its price target lifted by Piper Sandler from $620.00 to $725.00 in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has ...

A New York appellate court on Tuesday denied President-elect Donald Trump's bid to halt sentencing set for Friday for his conviction on criminal charges stemming from hush money paid to a porn ...